TM Editors Note: Many of the companies mentioned in this article are penny stocks and/or microcaps. Such stocks are readily manipulated; do your own careful due diligence.

This article tracks the performance of 15 of the 31 biopharmaceutical companies involved in the research and development of psychedelic compounds to treat mental health issues such as obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders in the munKNEE Psychedelic Stocks Index.

Index Inclusion Criteria

The 15 stocks eligible for inclusion in the index are based on the following criteria:

• a market capitalization between US$10M and US$200M
• a stock that trades between US$0.10/share and US$2/share

Below are the 15 eligible companies in the munKNEE Psychedelic Stocks Index and their performance on Wednesday, December 23rd in alphabetical order. Tuesday's performance for each is in brackets.

1. Better Plant (VEGGF) +10.2% (-11.4%)
2. Champignon (SHRMF) +5.6% (-14.7%)
3. Cybin (CLXPF) +1.0% (-11.8%)
4. Havn (HAVLF) -2.1% (-5.3%)
5. Hollister (HSTRF) +9.2% (-3.5%)
6. Jaguar (JAGX) +170.3% (+16.0%)
   • has signed a $6M agreement with a secured lender entitling the lender to receive 2.0x the Royalty Purchase Price of future royalties of its Mytesi (crofelemer) and lechlemerit products.
7. Mind Cure (MCURF) +1.7% (-9.1%)
8. Mydecine (MYCOF) N/C (-13.5%)
9. Nova Mentis (LIBFF) N/C (-12.5%)
10. Numinus (LKYSF) +11.4% (-24.7%)
11. Psyched Wellness (DCNPF) N/C (-6.8%)
12. Red Light (TRUFF) +11.2% (-12.6%)
13. Revive (RVVTF) +19.1% (-15.9)
14. Seelos (SEEL) +12.3% (+1.1%)
15. Silo Pharma (SILO) N/C (+7.1%)

The average performance of the above 15 psychedelic drug stocks on Wednesday was +27.3% vs. -18.7% vs. on Tuesday. To avoid duplication please refer to a previous article (see here) in which I provided introductory paragraphs on each of the above constituents.